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Objective: Type 2 diabetes mellitus (T2D) is a pathologically and genetically heterogeneous disease
inﬂuenced by genetic and environmental factors. This study aims to investigate the association between
T2D and polymorphism(s) in CREB-regulated transcription coactivator 3 (CRTC3) in Asian Taiwan.
Materials and methods: In this study, 417 participants with T2D and 197 without T2D were recruited.
Anthropometrics, the metabolic proﬁle, blood pressure, fasting plasma glucose, glycosylated hemoglobin
(HbA1c), serum triglycerides, serum total cholesterol, low-density lipoprotein, high-density lipoprotein
(HDL), and C-peptide were analyzed. TaqMan genotyping was used to identify individual genotypes, and
the association of CRTC3 polymorphism with clinical and biochemical parameters was assessed.
Results: Single nucleotide polymorphism (SNP) rs8033595 showed an association with diabetes
(p ¼ 0.031) and hyperlipidemia (p ¼ 0.002). Odds ratio analysis showed that A carriers (AA or AG) had a
protective effect against developing T2D and hyperlipidemia. Moreover, individuals with the GG geno-
type had higher frequencies of developing T2D and hyperlipidemia comorbidity.
Conclusion: In this study, conducted for the ﬁrst time in Asian Taiwan, rs8033595 of the CRTC3 gene was
associated with T2D and hyperlipidemia in our study population.
Copyright © 2014, Buddhist Compassion Relief Tzu Chi Foundation. Published by Elsevier Taiwan LLC. All
rights reserved.1. Introduction
Type 2 diabetes mellitus (T2D) results from complex in-
teractions between genetic and environmental factors [1e3]. Ac-
cording to the World Health Organization, the risk of developing
T2D is approximately 50% hereditary [4,5]. Genetic factors affecting
T2D prevalence include increasing age, ethnicity, a family history of
diabetes, and genetic variants. Environmental factors such as life-
style also contribute to the development of T2D, along with other
factors, including physical inactivity [6], obesity [7e10], and insulin
resistance [11].ces, Tzu Chi University, 701,
l.: þ886 3 8565301x2014;
elief Tzu Chi Foundation. PublisheGenome-wide association studies (GWASs), a type of
population-based association study, have been performed in a
systemic search for links between the genotype and phenotype of
candidate genes involved in complex diseases. GWASs can be used
to detect variations associated with diseases throughout the
genome. GWASs have shown six new gene regions related to T2D,
and these variants alter body mass index (BMI) and are associated
with obesity [12e17]. GWASs provide information that clariﬁes the
understanding of the genetic basis of common and complex dis-
eases and illustrate novel pathways, thus explaining ~10% of disease
heritability [18,19]. Common variations in the recognized genes
related to T2D identiﬁed by GWAS are as follows: TCF7L2, PPARG,
KCNJ11, WFS1, HNF1B, SLC30A8, HHEX, CDKAL1, IGF2BP2, CDKN2A/B,
FTO, JAZF1, CDC123-CAMK1D, TSPAN8-LGR5, THADA, ADAMTS9,
NOTCH2, and KCNQ1 [20e22]. The identiﬁcation of the TCF7L2 gene
as a T2D risk gene was unexpected [23]. The KCNQ1 gene was
recently discovered in the Japanese population [24,25]; PTPRD and
SRRwere reported in the Taiwanese population by Tsai et al in 2010d by Elsevier Taiwan LLC. All rights reserved.
Table 1
Clinical characteristics of the two groups.
Control T2D c2 t test p
n 197 417
Age (y) 57.2 ± 10.6 57.3 ± 9.6 0.179 0.86
Sex (M/F) 77/111 204/211 2.169 0.14
BMI (kg/m2) 23.407 ± 3.475 25.021 ± 4.7107 4.2090 <0.0001
Weight (kg) 61.50 ± 10.73 65.72 ± 12.145 4.1683 <0.0001
Waist (cm) 80.39 ± 9.427 88.8 ± 10.278 9.7148 <0.0001
Hip (cm) 95.06 ± 6.247 98.02 ± 8.502 4.3612 <0.0001
Waist:hip ratio 0.846 ± 0.092 0.901 ± 0.075 7.8701 <0.0001
HDL (mg/dL) 41.45 ± 12.14 45.741 ± 13.63 3.7683 <0.0002
Sex (n) M 82 206 3.249 0.071
F 115 211
Hypertension - 145 60 241.716 <0.0001
þ 42 357
Hyperlipidemia - 84 57 77.027 <0.0001
þ 104 357
Waista - 145 186 55.317 <0.0001
þ 43 231
BMI ¼ body mass index; F ¼ female; HDL ¼ high-density lipoprotein; M ¼ male;
T2D ¼ type 2 diabetes mellitus.
a Deﬁned as waist circumference <90 cm in males, <80 cm in females; þ deﬁned
as waist circumference90 cm in men,80 cm in women. The total sample count is
inconsistent in the control group, because the clinical data for some individuals
were unavailable.
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several genetic associations with T2D. However, association and
linkage studies on T2D showed inconsistent results that were not
reproducible when applied to multiple populations [27,28].
The CREB-regulated transcription coactivator 3 (CRTC3) gene is a
member of the CRTC family, which includes CRTC1, CRTC2, and
CRTC3. The members are distinguished by their expression proﬁles
and they are conserved in mammals [29e34]. CRTC3 contributes to
lipolysis and fatty acid oxidation inﬂuences the accumulation of
brown fat cells and burns the fat of white fat cells to maintain body
temperature [35,36]. A common human CRTC3 variant was found to
increase transcriptional activity and was associated with adiposity
in two distinct Mexican-American cohorts. The results suggest that
adipocyte CRTC3 plays a role in the development of obesity in
humans. We therefore supposed that CRTC3 is a candidate gene
associated with T2D. We studied 417 patients with T2D and 197
controls to investigate the association between their anthropo-
metric characteristics and selected single nucleotide poly-
morphisms (SNPs) ofCRTC3.Wealso evaluated the associationof the
selected SNPswith other symptoms related tometabolic syndrome.
2. Materials and methods
2.1. Clinical sample collection
The T2D group consisted of 417 Taiwanese patients who were
recruited from Chang Gung Memorial Hospital in Keelung, Taiwan.
All of the recruited patients fulﬁlled the following criteria: (1) aged
30e75 years; (2) had been diagnosed with diabetes for >5 years;
(3) fasting plasma glucose > 6.93 mmol/L (126 mg/dL); and (4)
glycosylated hemoglobin (HbA1c) > 6%. In addition, we recruited
197 individuals as the control group from the same hospital. The
control participants underwent blood pressure measurement and
laboratory tests, including blood biochemistry [fasting plasma
glucose, HbA1c, serum triglycerides, serum total cholesterol, low-
density lipoprotein, high-density lipoprotein (HDL), and C-pep-
tide] to rule out T2D. The Institutional Review Board of Chang Gung
Memorial Hospital approved the study protocol, and informed
written consent was obtained from each participant prior to when
the study was conducted.
2.2. DNA preparation
Genomic DNA was extracted from each participant's blood
sample using the QIAamp DNA Blood kit (Qiagen, Hilden, Germany
(operational)), according to the manufacturer's instructions. The
extractedgenomicDNAwasanalyzedbyagarosegel electrophoresis,
quantiﬁed by spectrophotometry, and stored at 80C until use.
2.3. SNP genotyping
Genotyping was performed on the SNPs rs8033595 (CRTC3
S72N) and rs7179095 (CRTC3 30 UTR) using the Taqman SNP gen-
otyping assay [Applied Biosystems (ABI), Forest City, CA, USA]. The
primers and probes for the selected SNPs were included in the ABI
Assay-on-Demand Kit. Reactions were performed according to the
manufacturer's protocol. The ﬂuorescent probe was detected using
the ABI Prism 7900 Real-Time PCR System (ABI Life Technologies,
Foster City, California, United States).
2.4. Statistical analysis
The quality of the genotype data was evaluated using Hardy-
Weinberg equilibrium (HWE) proportion tests. Single-point asso-
ciation analyses were performed using c2 and t tests. The datawerefurther evaluated using logistic regression adjusted for other fac-
tors in an odds ratio analysis. The logistic regression and odds ratio
analysis were performed using SPSS version 17 (SPSS Inc., Chicago,
IL, USA).
3. Results
3.1. Characteristics of the participants
The study consisted of 614 Taiwanese adults (417 T2D patients
and 197 control individuals). The mean age of the participants was
57.25 ± 10.1 years (57.2 ± 10.6 and 57.3 ± 9.6 years for the T2D
patients and controls, respectively). The mean duration of patho-
genesis of T2D was 14.07 ± 7.16 years (range, 1e42 years). A com-
parison of the results of anthropometric measurements of cases
and controls showed that the BMI, weight, waist circumference, hip
circumference, waist-to-hip ratio (W-HR), and HDL values were
signiﬁcantly different between the two groups, with no signiﬁcant
differences in the prevalence by gender. The ﬁve indicators for
metabolic disease are: (1) fasting glucose level; (2) blood pressure;
(3) HDL cholesterol level; (4) triglyceride level; and (5) waist
circumference. Low levels of HDL cholesterol indicate a risk of
hyperlipidemia. In our cohorts, there were signiﬁcant differences in
hyperlipidemia and hypertension between the control participants
and the T2D patients, as shown in Table 1.
3.2. Genotype associated with the spectrum of clinical symptoms
The two selected SNPs, rs8033595 and rs7179095, were geno-
typed and analyzed in our participants. The genotyping frequency
distribution of selected SNPs was not derived from HWE. The
rs8033595 SNP showed nominal association with the anthropo-
metric indices of T2D in our cohort (Table 2). SNP rs8033595 was
also associated with hyperlipidemia in our study participants
(Table 3). In addition, odds ratio analysis was performed for dia-
betes and hyperlipidemia using logistic regression, after adjusting
for other signiﬁcant factors (Table 4). A-carriers, including those
with AG þ GG, had a lower risk of association with diabetes and
hyperlipidemia. Thus, the A allele was protective against the
development of diabetes or hyperlipidemia (Table 4). The other
Table 2
Genotype analysis of type 2 diabetes mellitus (T2D) patients compared with
controls.
SNP Genotype n c2 p
Control T2D
rs8033595 AA 9 (5) 7 (2) 6.973 0.031
AG 64 (32) 113 (27)
GG 124 (63) 297 (71)
rs7179095 AA 25 (13) 38 (9) 2.768 0.251
AG 87 (44) 175 (42)
GG 85 (43) 204 (49)
Data are presented as n (%).
SNP ¼ single nucleotide polymorphism.
Table 4
Odds ratio (OR) analysis for the A allele of rs8033595 in diabetes and hyperlipidemia.
Phenotype Genotype Count OR (95% CI) p
Control Case
Diabetesa Without With
AA 9 (5) 7 (2) 0.166 (0.039, 0.715) 0.016
AG 64 (32) 113 (27) 0.751 (0.446, 1.300) 0.318
GG (ref.) 124 (63) 297 (71) 1
Hyperlipidemiab Without With
AA 7 (5) 9 (2) 0.459 (0.153, 1.376) 0.164
AG 58 (38) 119 (26) 0.573 (0.374, 0.879) 0.011
GG (ref.) 88 (58) 333 (72) 1
Data are presented as n (%), unless otherwise indicated.
CI ¼ conﬁdence interval.
a Adjusted by sex, hypertension, hyperlipidemia, and waist size.
b Adjusted by sex, hypertension, diabetes, and waist size.
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association with the genotype, but the results were not statistically
signiﬁcant (data not shown).
3.3. The rs8033595 SNP is associated with T2D and hyperlipidemia
comorbidity
The association of the selected SNPs with T2D and hyperlipid-
emia comorbidity was further examined by the c2 test. A signiﬁcant
p value for rs8033595 revealed that the relationship of the
rs8033595 genotype and T2D and hyperlipidemia comorbidity was
independent. The results indicated that T2D and hyperlipidemia
comorbidity were associated with the rs8033595 genotypes, but
not rs7179095 (Table 5).
A high percentage of the individuals with the G/G and A/G ge-
notypes were found to have diabetes and hyperlipidemia comor-
bidities, indicating that rs8033595 is associated with the symptoms
of metabolic syndrome, especially in patients with both T2D and
hyperlipidemia (Fig. 1).
4. Discussion
T2D mellitus is the most common endocrine disease, charac-
terized clinically by peripheral insulin resistance, disruption ofTable 3
Clinical characteristics of participants for genotype testing analysis.
Clinical
characteristic
SNP Genotype n c2 p
Control Case
Hypertension Without With
rs8033595 AA 5 (2) 10 (3) 0.111 0.946
AG 55 (27) 114 (29)
GG 145 (71) 275 (69)
rs7179095 AA 27 (13) 36 (9) 2.400 0.301
AG 85 (40) 176 (44)
GG 102 (48) 187 (47)
Hyperlipidemia without With
rs8033595 AA 7 (5) 9 (2) 12.491 0.002
AG 58 (38) 119 (26)
GG 88 (58) 333 (72)
rs7179095 AA 16 (10) 47 (10) 2.409 0.300
AG 73 (48) 189 (41)
GG 64 (42) 225 (49)
Waist without With
rs8033595 AA 10 (3) 6 (2) 1.636 0.441
AG 104 (31) 73 (27)
GG 226 (66) 195 (71)
rs7179095 AA 35 (10) 28 (10) 0.466 0.792
AG 149 (44) 113 (41)
GG 156 (46) 133 (49)
Data are presented as n (%).
SNP ¼ single nucleotide polymorphism.glucose uptake, and pancreatic islet b-cell failure. We analyzed the
association between the CRTC3 gene and T2D in the Taiwanese
population. The results showed that functional SNP rs8033595
(S72N) was associated with both T2D and hyperlipidemia in our
study population.
Weight gain is known as an important factor contributing to the
development of T2D. Several genes related to obesity have been
described, including the following: IRS1 gives rise to increased
levels of bad cholesterol and blood glucose concentration [37];
BRD2 reduces inﬂammation in fat cells and prevents b-cell failure in
the pancreas, thereby protecting against obesity-induced diabetes
[38]; CMAH decreases insulin production [39]; ZFP69 affects blood
sugar levels and the malfunction of fat metabolism [40]; and the
CRTC family is insulin-sensitive under high fat diet conditions and
reduces hepatic glucose output. The CRTC3 genewas recently found
to play a role inweight gain, and its polymorphismwas found to be
associated with obesity [29e36].
The CREB coactivator (CRTC3) promotes obesity by attenuating
the b-adrenergic receptor signaling pathway, this response having
been activated by catecholamine signals. The catecholamine signal
pathway is related to the adipose-derived hormone leptin and
maintains energy balance by burning fat. It is believed to disrupt
adipocytokine signaling, leading to the development of insulin
resistance [35]. Peroxisome proliferator-activated receptor gamma
coactivator 1-alpha (PGC-1a) is regulated by the CREB proteins in
mitochondrial biogenesis in liver cells. The CRTC3 expression
involved in this mechanism is silenced in response to PGC-1a in-
duction due to rotenone inhibition, and blocks downstream mito-
chondrial biogenesis [11,36]. Dysfunction of mitochondria leads to
impaired insulin secretion, causing hyperglycemia, hyperinsulin-
ism, and the development of T2D [9,19]. Overexpression of CRTC3
increases mitochondrial biogenesis, affecting both glucose utiliza-
tion and fatty acid oxidation. CRTC3 activates translation through
the CRE sites in the SIK/TORC signaling pathway and regulates theTable 5
Association of CRTC3 polymorphisms with diabetes/hyperlipidemia comorbidity.a
SNP Genotype 0 1 2 c2 p
rs8033595 AA 6 40 47 19.353 0.001
AG 4 42 118
GG 6 95 256
rs7179095 AA 9 46 38 5.925 0.205
AG 23 68 73
GG 31 148 178
SNP ¼ single nucleotide polymorphism.
a Clinical phenotypes were deﬁned as 0 ¼ neither diabetes nor hyperlipidemia,
1 ¼ diabetes or hyperlipidemia, 2 ¼ with both diabetes and hyperlipidemia. The p
values were generated using 33 c2 test.
Fig. 1. Three genotypes of single nucleotide polymorphism (SNP) rs8033595 with
different frequencies of phenotype distribution. The ﬁrst phenotype group had neither
diabetes nor hyperlipidemia, the second phenotype group had diabetes or hyperlip-
idemia, and the ﬁnal phenotype group had both diabetes and hyperlipidemia. The
p value was generated by the 33 c2 test according to the number of participants in
Table 5.
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[35,36,41,42].
CRTC3 may be a switch to control the number of brown fat cells
that control obesity by attenuating b-adrenergic receptor signaling
in adipocyte tissues, and maintaining energy balance by reducing
adenyl cyclase activity by upregulating the expression of RGS2.
CRTC3 should contribute to the development of insulin resistance
and T2D. In a previous study, the 72N allele was associated with
BMI in Mexican-Americans, but not in non-Hispanic whites [35].
The association between T2D and CRTC3 is still not clear. We
observed a CRTC3 variant allele, rs8033595 G > A, that encodes
a missense variant (serine changed to asparagine), and rs7179095
(A/G) in the 30 UTR region (in a putative miRNA-4761-5p binding
site identiﬁed by a miRBase search) in the Human Database of
Single Nucleotide Polymorphisms. In our study, the T2D cohort
showed that T2D and hyperlipidemia are associated with the
rs8033595 SNP, which is one of 2233 SNPs located in the coding
region of the forward strand. It is a missense variant (G to A)
encoding a protein inwhich serine is mutated to asparagine (S72N).
Our results show that CRTC3 increases the risk of hyperlipidemia;
thus, it provides insight in the context of a physiologically relevant
system for lipid metabolism and glucose uptake mechanisms. In-
dividuals with the CRTC3 risk allele have a higher chance of
developing both diabetes and hyperlipidemia than those without
this allele.
SNP rs8033595 (S72N) was associated with both T2D and
hyperlipidemia in our study population. Its presence indicated a
risk of both T2D and hyperlipidemia in individuals homozygous for
the G allele and should be evaluated further in prospective studies.
This is the ﬁrst data demonstrating the association of a genetic
variant with T2D and hyperlipidemia comorbidity in the Taiwan
population. The genetic role of this association as well as that of
other CRTC3 SNPs warrants further investigation, both in Han
populations living in different geographic regions and in other
Asian populations.
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